Daiichi-Sankyo Consolidates In Europe

Japan's Daiichi-Sankyo is to redouble efforts to expand in Europe. Sankyo alone had sales of EUR322mn (US$406mn) in the region last year. With over 1,000 sales representatives already employed in the region, the company also hopes to benefit from a new co-marketing deal on US firm Eli Lilly's osteoporosis treatment Evista (raloxifene). The arrangement, which marks a new area of therapeutic focus for the Japanese company, will cover the major Western European markets except France, Spain and the

To read the full article, please sign in or take a free trial.